Evidence map›Paper›PMID 22745797›Full record

ArticlePloS one2012

Divergent responses of different endothelial cell types to infection with Candida albicans and Staphylococcus aureus.

Kati Seidl, Norma V Solis, Arnold S Bayer, Wessam Abdel Hady, Steven Ellison, Meredith C Klashman, Yan Q Xiong, Scott G Filler

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. The Complex Intracellular Lifecycle ofInternational journal of molecular sciences · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Identification of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Linezolid and Rifampicin Combination to CombatFrontiers in microbiology · 2019
    Article
  11. Frontiers in microbiology · 2019
    Review
  12. The ArlRS two-component system is a regulator of Staphylococcus aureus-induced endothelial cell damage.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Article
  13. Article
  14. Host cell invasion by medically important fungi.Cold Spring Harbor perspectives in medicine · 2014
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kati SeidlLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America.
Norma V Solis
Arnold S Bayer
Wessam Abdel Hady
Steven Ellison
Meredith C Klashman
Yan Q Xiong
Scott G Filler
The Lundquist Institute · USHarbor–UCLA Medical Center · USUniversity of Zurich · CH

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Staphylococcal Adaptations to Platelet Microbicidal ProteinR01AI039108 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI BAYER, ARNOLD S · 1997 to 2016
$5.1M
Candida Invasion of Endothelium and VirulenceR01AI054928 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI FILLER, SCOTT G · 2004 to 2013
$2.9M
NCATS NIH HHS UL1 TR000124NIAID NIH HHS R01 AI039108NIAID NIH HHS R01 AI054928NIAID NIH HHS R01AI054928NIAID NIH HHS R01AI39108PHS HHS UL1TR000124
6 · The paper itself

Abstract

Endothelial cells are important in the pathogenesis of bloodstream infections caused by Candida albicans and Staphylococcus aureus. Numerous investigations have used human umbilical vein endothelial cells (HUVECs) to study microbial-endothelial cell interactions in vitro. However, the use of HUVECs requires a constant supply of umbilical cords, and there are significant donor-to-donor variations in these endothelial cells. The use of an immortalized endothelial cell line would obviate such difficulties. One candidate in this regard is HMEC-1, an immortalized human dermal microvascular endothelial cell line. To determine if HMEC-1 cells are suitable for studying the interactions of C. albicans and S. aureus with endothelial cells in vitro, we compared the interactions of these organisms with HMEC-1 cells and HUVECs. We found that wild-type C. albicans had significantly reduced adherence to and invasion of HMEC-1 cells as compared to HUVECs. Although wild-type S. aureus adhered to and invaded HMEC-1 cells similarly to HUVECs, an agr mutant strain had significantly reduced invasion of HMEC-1 cells, but not HUVECs. Furthermore, HMEC-1 cells were less susceptible to damage induced by C. albicans, but more susceptible to damage caused by S. aureus. In addition, HMEC-1 cells secreted very little IL-8 in response to infection with either organism, whereas infection of HUVECs induced substantial IL-8 secretion. This weak IL-8 response was likely due to the anatomic site from which HMEC-1 cells were obtained because infection of primary human dermal microvascular endothelial cells with C. albicans and S. aureus also induced little increase in IL-8 production above basal levels. Thus, C. albicans and S. aureus interact with HMEC-1 cells in a substantially different manner than with HUVECs, and data obtained with one type of endothelial cell cannot necessarily be extrapolated to other types.

Indexed as

Candida albicansCells, CulturedEndothelial CellsHost-Pathogen InteractionsHumansHuman Umbilical Vein Endothelial CellsInterleukin-8Staphylococcus aureusInterleukin-8

Identifiers

PMID22745797
PMCPMC3382135
OpenAlexW1989386278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.